Recent advances in the understanding of the role of nitric oxide in cardiovascular homeostasis
- PMID: 15949847
- DOI: 10.1016/j.pharmthera.2005.04.005
Recent advances in the understanding of the role of nitric oxide in cardiovascular homeostasis
Abstract
Nitric oxide synthases (NOS) are the enzymes responsible for nitric oxide (NO) generation. To date, 3 distinct NOS isoforms have been identified: neuronal NOS (NOS1), inducible NOS (NOS2), and endothelial NOS (NOS3). Biochemically, NOS consists of a flavin-containing reductase domain, a heme-containing oxygenase domain, and regulatory sites. NOS catalyse an overall 5-electron oxidation of one Nomega-atom of the guanidino group of L-arginine to form NO and L-citrulline. NO exerts a plethora of biological effects in the cardiovascular system. The basal formation of NO in mitochondria by a mitochondrial NOS seems to be one of the main regulators of cellular respiration, mitochondrial transmembrane potential, and transmembrane proton gradient. This review focuses on recent advances in the understanding of the role of enzyme and enzyme-independent NO formation, regulation of NO bioactivity, new aspects of NO on cardiac function and morphology, and the clinical impact and perspectives of these recent advances in our knowledge on NO-related pathways.
Similar articles
-
Cardiac myocyte neuronal nitric oxide synthase. New therapeutic target in heart failure?Arch Mal Coeur Vaiss. 2005 Dec;98(12):1244-8. Arch Mal Coeur Vaiss. 2005. PMID: 16435605 Review.
-
Regulation of endothelial nitric oxide synthase: involvement of protein kinase G 1 beta, serine 116 phosphorylation and lipid structures.Clin Exp Pharmacol Physiol. 2008 Feb;35(2):148-58. doi: 10.1111/j.1440-1681.2007.04801.x. Epub 2007 Sep 24. Clin Exp Pharmacol Physiol. 2008. PMID: 17892503
-
Structure-function studies on nitric oxide synthases.J Inorg Biochem. 2005 Jan;99(1):293-305. doi: 10.1016/j.jinorgbio.2004.10.016. J Inorg Biochem. 2005. PMID: 15598508 Review.
-
Constitutive nitric oxide synthases in the heart from hypertrophy to failure.Clin Exp Pharmacol Physiol. 2008 Apr;35(4):483-8. doi: 10.1111/j.1440-1681.2008.04901.x. Clin Exp Pharmacol Physiol. 2008. PMID: 18307746 Review.
-
Nitric oxide and the endothelium: history and impact on cardiovascular disease.Vascul Pharmacol. 2006 Nov;45(5):268-76. doi: 10.1016/j.vph.2006.08.002. Epub 2006 Aug 17. Vascul Pharmacol. 2006. PMID: 17052961 Review.
Cited by
-
Mitochondriocentric pathway to cardiomyocyte necrosis in aldosteronism: cardioprotective responses to carvedilol and nebivolol.J Cardiovasc Pharmacol. 2011 Jul;58(1):80-6. doi: 10.1097/FJC.0b013e31821cd83c. J Cardiovasc Pharmacol. 2011. PMID: 21558884 Free PMC article.
-
Synthesis of Nitric Oxide-Releasing Polyurethanes with S-Nitrosothiol-Containing Hard and Soft Segments.Polym Chem. 2011 Apr;2(4):906-913. doi: 10.1039/C0PY00269K. Epub 2011 Feb 16. Polym Chem. 2011. PMID: 23418409 Free PMC article.
-
Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.Mol Diagn Ther. 2012 Oct;16(5):285-302. doi: 10.1007/s40291-012-0002-7. Mol Diagn Ther. 2012. PMID: 23018631 Review.
-
Arginase inhibition augments nitric oxide production and facilitates left ventricular systolic function in doxorubicin-induced cardiomyopathy in mice.Physiol Rep. 2014 Sep 28;2(9):e12130. doi: 10.14814/phy2.12130. Print 2014 Sep 1. Physiol Rep. 2014. PMID: 25263201 Free PMC article.
-
Protein-protein interaction network-based integration of GWAS and functional data for blood pressure regulation analysis.Hum Genomics. 2024 Feb 8;18(1):15. doi: 10.1186/s40246-023-00565-6. Hum Genomics. 2024. PMID: 38326862 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources